Ellinor I B Peerschke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/210548/publications.pdf

Version: 2024-02-01

65 papers 3,489 citations

28 h-index 57 g-index

65 all docs

65 does citations

65 times ranked 4375 citing authors

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes. Journal of Thrombosis and Haemostasis, 2022, 20, 2046-2057. | 3.8 | 8 |
| 2 | Choosing wisely during the COVID-19 pandemic: optimising outpatient cancer care while conserving resources with a new algorithm to report automated ANC results. Journal of Clinical Pathology, 2021, 74, 202-204. | 2.0 | 0 |
| 3 | Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 229-250. | 4.5 | 27 |
| 4 | Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. Annals of Neurology, 2021, 90, 159-169. | 5.3 | 31 |
| 5 | Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. Frontiers in Immunology, 2021, 12, 716361. | 4.8 | 9 |
| 6 | Heritable platelet disorders: an enigma even guidelines can't unravel. British Journal of Haematology, 2021, 195, 13-14. | 2.5 | 0 |
| 7 | SARS-CoV-2 Exacerbates COVID-19 Pathology Through Activation of the Complement and Kinin Systems. Frontiers in Immunology, 2021, 12, 767347. | 4.8 | 28 |
| 8 | Anti gC1qR/p32/HABP1 Antibody Therapy Decreases Tumor Growth in an Orthotopic Murine Xenotransplant Model of Triple Negative Breast Cancer. Antibodies, 2020, 9, 51. | 2.5 | 5 |
| 9 | SLE: Novel Postulates for Therapeutic Options. Frontiers in Immunology, 2020, 11, 583853. | 4.8 | 6 |
| 10 | gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma. Frontiers in Oncology, 2020, 10, 1413. | 2.8 | 13 |
| 11 | Developing Quality Programs for Cell-Free DNA (cfDNA) Extraction from Peripheral Blood. journal of applied laboratory medicine, The, 2020, 5, 788-797. | 1.3 | 6 |
| 12 | Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 2020, 583, 127-132. | 27.8 | 483 |
| 13 | Heterozygous P32/C1QBP/HABP1 Polymorphism rs56014026 Reduces Mitochondrial Oxidative Phosphorylation and Is Expressed in Low-grade Colorectal Carcinomas. Frontiers in Oncology, 2020, 10, 631592. | 2.8 | 4 |
| 14 | Complement and coagulation: key triggers of COVID-19–induced multiorgan pathology. Journal of Clinical Investigation, 2020, 130, 5674-5676. | 8.2 | 27 |
| 15 | Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy. Frontiers in Oncology, 2019, 9, 1042. | 2.8 | 10 |
| 16 | The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1)1. Seminars in Immunology, 2019, 45, 101338. | 5.6 | 52 |
| 17 | Is the A-Chain the Engine That Drives the Diversity of C1q Functions? Revisiting Its Unique Structure. Frontiers in Immunology, 2018, 9, 162. | 4.8 | 13 |
| 18 | HITTING the Diagnosis. American Journal of Clinical Pathology, 2018, 150, 116-120. | 0.7 | 2 |

| # | Article | IF | Citations |
|----|---|-----|-----------|
| 19 | C1q as an autocrine and paracrine regulator of cellular functions. Molecular Immunology, 2017, 84, 26-33. | 2.2 | 30 |
| 20 | Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11. | 3.0 | 36 |
| 21 | The Coags Uncomplicated App: Fulfilling Educational Gaps Around Diagnosis and Laboratory Testing of Coagulation Disorders. JMIR Medical Education, 2017, 3, e6. | 2.6 | 3 |
| 22 | Analysis of the Interaction between Globular Head Modules of Human C1q and Its Candidate Receptor gC1qR. Frontiers in Immunology, 2016, 7, 567. | 4.8 | 16 |
| 23 | Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine. Critical Care Medicine, 2016, 44, 2251-2257. | 0.9 | 92 |
| 24 | Identification of the gC1qR sites for the HIV-1 viral envelope protein gp41 and the HCV core protein: Implications in viral-specific pathogenesis and therapy. Molecular Immunology, 2016, 74, 18-26. | 2.2 | 17 |
| 25 | The complement and contact activation systems: partnership in pathogenesis beyond angioedema. Immunological Reviews, 2016, 274, 281-289. | 6.0 | 41 |
| 26 | Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocritical Care, 2016, 24, 6-46. | 2.4 | 550 |
| 27 | Consensus Guidelines for Practical Competencies in Anatomic Pathology and Laboratory Medicine for the Undifferentiated Graduating Medical Student. Academic Pathology, 2015, 2, 2374289515605336. | 1.1 | 8 |
| 28 | Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections. Transfusion, 2015, 55, 2001-2009. | 1.6 | 25 |
| 29 | Reference Range Determination for Whole-Blood Platelet Aggregation Using the Multiplate Analyzer. American Journal of Clinical Pathology, 2014, 142, 647-656. | 0.7 | 53 |
| 30 | cC1qR/CR and gC1qR/p33: Observations in cancer. Molecular Immunology, 2014, 61, 100-109. | 2.2 | 55 |
| 31 | Using the Hemoglobin Content of Reticulocytes (RET-He) to Evaluate Anemia in Patients With Cancer. American Journal of Clinical Pathology, 2014, 142, 506-512. | 0.7 | 24 |
| 32 | Soluble gC1qR Is an Autocrine Signal That Induces B1R Expression on Endothelial Cells. Journal of Immunology, 2014, 192, 377-384. | 0.8 | 32 |
| 33 | Monocyte Expressed Macromolecular C1 and C1q Receptors as Molecular Sensors of Danger: Implications in SLE. Frontiers in Immunology, 2014, 5, 278. | 4.8 | 32 |
| 34 | Purification of C1q Receptors and Functional Analysis. Methods in Molecular Biology, 2014, 1100, 319-327. | 0.9 | 5 |
| 35 | Targeting gC1qR Domains for Therapy Against Infection and Inflammation. Advances in Experimental Medicine and Biology, 2013, 735, 97-110. | 1.6 | 16 |
| 36 | gC1qR Expression in Normal and Pathologic Human Tissues. Journal of Histochemistry and Cytochemistry, 2012, 60, 467-474. | 2.5 | 45 |

| # | Article | IF | Citations |
|----|---|-----|-----------|
| 37 | The C1q Family of Proteins: Insights into the Emerging Non-Traditional Functions. Frontiers in Immunology, 2012, 3, . | 4.8 | 87 |
| 38 | Cell Surface Expression and Function of the Macromolecular C1 Complex on the Surface of Human Monocytes. Frontiers in Immunology, 2012, 3, 38. | 4.8 | 20 |
| 39 | DC-SIGN, C1q, and gC1qR form a trimolecular receptor complex on the surface of monocyte-derived immature dendritic cells. Blood, 2012, 120, 1228-1236. | 1.4 | 62 |
| 40 | Blockade of gC1qR/p33, a receptor for C1q, inhibits adherence of Staphylococcus aureus to the microvascular endothelium. Microvascular Research, 2011, 82, 66-72. | 2.5 | 14 |
| 41 | Structure?Function Studies Using Deletion Mutants Identify Domains of gC1qR/p33 as Potential Therapeutic Targets for Vascular Permeability and Inflammation. Frontiers in Immunology, 2011, 2, . | 4.8 | 21 |
| 42 | Complement activation on platelets: Implications for vascular inflammation and thrombosis. Molecular Immunology, 2010, 47, 2170-2175. | 2.2 | 203 |
| 43 | Evidence that a $C1q/C1qR$ system regulates monocyte-derived dendritic cell differentiation at the interface of innate and acquired immunity. Innate Immunity, 2010, 16, 115-127. | 2.4 | 55 |
| 44 | Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. Journal of Allergy and Clinical Immunology, 2009, 124, 1303-1310.e4. | 2.9 | 94 |
| 45 | Regulated complement deposition on the surface of human endothelial cells: Effect of tobacco smoke and shear stress. Thrombosis Research, 2008, 122, 221-228. | 1.7 | 35 |
| 46 | C1q is a molecular switch dictating the monocyte to dendritic cell (DC) transition and arrests DCs in an immature phenotype. FASEB Journal, 2008, 22, 673.1. | 0.5 | 3 |
| 47 | Examination of Platelet Function in Whole Blood Under Dynamic Flow Conditions With the Cone and Plate(let) Analyzer. American Journal of Clinical Pathology, 2007, 127, 422-428. | 0.7 | 23 |
| 48 | The contribution of gC1qR/p33 in infection and inflammation. Immunobiology, 2007, 212, 333-342. | 1.9 | 80 |
| 49 | Classical pathway complement activation on human endothelial cells. Molecular Immunology, 2007, 44, 2228-2234. | 2.2 | 33 |
| 50 | Proposed Research Training Guidelines for Residents in Laboratory Medicine. Clinics in Laboratory Medicine, 2007, 27, 241-253. | 1.4 | 9 |
| 51 | gC1qR/p33 Blockade Reduces Staphylococcus aureus Colonization of Target Tissues in an Animal Model of Infective Endocarditis. Infection and Immunity, 2006, 74, 4418-4423. | 2.2 | 39 |
| 52 | Activation of the Classical Pathway of Complement by Resting and Shear Stress-Stimulated Human Endothelial Cells Blood, 2005, 106, 2664-2664. | 1.4 | 1 |
| 53 | Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists. British Journal of Haematology, 2004, 127, 195-203. | 2.5 | 18 |
| 54 | Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. International Journal of Cancer, 2004, 110, 741-750. | 5.1 | 83 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | cC1q-R (calreticulin) and gC1q-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection. Molecular Immunology, 2004, 41, 173-183. | 2.2 | 133 |
| 56 | Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesions. Molecular Immunology, 2004, 41, 759-766. | 2.2 | 56 |
| 57 | Complement component C1q induces endothelial cell adhesion and spreading through a docking/signaling partnership of C1q receptors and integrins. International Immunopharmacology, 2003, 3, 299-310. | 3.8 | 13 |
| 58 | Role of C1q and C1q Receptors in the Pathogenesis of Systemic Lupus Erythematosus. , 2003, 7, 87-97. | | 46 |
| 59 | Activation-dependent surface expression of gC1qR/p33 on human blood platelets. Thrombosis and Haemostasis, 2003, 89, 331-9. | 3.4 | 24 |
| 60 | Cooperation of C1q Receptors and Integrins in C1q-Mediated Endothelial Cell Adhesion and Spreading. Journal of Immunology, 2002, 168, 2441-2448. | 0.8 | 80 |
| 61 | The laboratory evaluation of platelet dysfunction. Clinics in Laboratory Medicine, 2002, 22, 405-420. | 1.4 | 24 |
| 62 | gC1q-R/p33: Structure-Function Predictions from the Crystal Structure. Immunobiology, 2002, 205, 421-432. | 1.9 | 53 |
| 63 | Human blood platelet gC1qR/p33. Immunological Reviews, 2001, 180, 56-64. | 6.0 | 37 |
| 64 | gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection. Immunological Reviews, 2001, 180, 65-77. | 6.0 | 166 |
| 65 | Staphylococcus aureus Protein A Recognizes Platelet gC1qR/p33: a Novel Mechanism for Staphylococcal Interactions with Platelets. Infection and Immunity, 2000, 68, 2061-2068. | 2.2 | 173 |